Skip to content

behavioral activation play therapy for adolescents with depression

Study on the intervention effect of behavioral activation play therapy for adolescents with depression

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300072671
Enrollment
Unknown
Registered
2023-06-20
Start date
2023-07-01
Completion date
Unknown
Last updated
2023-06-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adolescents with depression

Interventions

Study group:behavioral activation play therapy for adolescents with depression
Control group:Brief behavioral activation therapy

Sponsors

The Affiliated Brain Hospital of Guangzhou Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
12 Years to 17 Years

Inclusion criteria

Inclusion criteria: 1.DSM-5 diagnosis of depression (including single episode, recurring episode). 2.Montgomery Depression Rating Scale (MADRS) score =12. 3.Age 12-17 years. 4.Patients with intelligence level in the normal range, normal perception, self-expression ability, can complete the baseline scale assessment. 5.Written informed consent from his or her legal guardian is required.

Exclusion criteria

Exclusion criteria: 1.Other mental disorders that meet DSM-5 diagnostic criteria, including organic mental disorders, mental retardation, autism spectrum disorders, schizophrenia, bipolar disorder, eating disorders, obsessive-compulsive disorder, alcohol dependence, drug dependence/abuse, etc. 2.Patients with illness or emotional instability, current positive suicidal ideation (Montgomery Depression Rating Scale suicide score > 4), severe destructive and aggressive behavior. 3.Severe psychotic symptoms (presence of painful or common hallucinations and/or delusions). 4.Combined with serious physical illness and/or evidence that the patient has clinically significant, uncontrolled or unstable cardiovascular, kidney, liver, gastrointestinal, blood, immune, endocrine, metabolic, or pulmonary disease (as determined by history, clinical laboratory or ECG findings, or physical examination) that increases the risk of intervention or confuses the interpretation of the study results; 5.According to the research group, patients who could not cooperate with the cognitive function examiner or were not suitable for this study.

Design outcomes

Primary

MeasureTime frame
Montgomery-Asberg Depression Rating Scale (MADRS);

Secondary

MeasureTime frame
BDI-II (Beck Depression Inventory);behavioral inhibition-activation system scale, BIS-BAS scale;Insomnia Severity Index,ISI;International Physical Activity Questionnaire;Level 5 Likert rating Acceptance questionnaire;Adolescent Self-harm Behavior Questionnaire, ASHBQ;

Countries

China

Contacts

Public ContactXiaolong Huang

The Affiliated Brain Hospital of Guangzhou Medical University

3089954242@qq.com+86 20 8126 8002

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 6, 2026